DK1414858T3 - Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf - Google Patents

Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf

Info

Publication number
DK1414858T3
DK1414858T3 DK02726398T DK02726398T DK1414858T3 DK 1414858 T3 DK1414858 T3 DK 1414858T3 DK 02726398 T DK02726398 T DK 02726398T DK 02726398 T DK02726398 T DK 02726398T DK 1414858 T3 DK1414858 T3 DK 1414858T3
Authority
DK
Denmark
Prior art keywords
mammal
camelide
preparation
vhh antibodies
single chain
Prior art date
Application number
DK02726398T
Other languages
English (en)
Inventor
Frank Grosveld
Original Assignee
Univ Erasmus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Erasmus filed Critical Univ Erasmus
Application granted granted Critical
Publication of DK1414858T3 publication Critical patent/DK1414858T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Environmental Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
DK02726398T 2001-04-24 2002-04-24 Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf DK1414858T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0110029.6A GB0110029D0 (en) 2001-04-24 2001-04-24 Transgenic animal
PCT/IB2002/002303 WO2002085944A2 (en) 2001-04-24 2002-04-24 Single chain camelid vhh antibodies, method for their production in a mammal and their uses

Publications (1)

Publication Number Publication Date
DK1414858T3 true DK1414858T3 (da) 2007-07-09

Family

ID=9913359

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02726398T DK1414858T3 (da) 2001-04-24 2002-04-24 Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf

Country Status (16)

Country Link
US (6) US20040137570A1 (da)
EP (2) EP1414858B1 (da)
JP (3) JP2005503129A (da)
CN (2) CN1518559A (da)
AT (1) ATE358730T1 (da)
AU (1) AU2002256866B2 (da)
BR (2) BR0209207A (da)
CA (2) CA2445255A1 (da)
CY (1) CY1107669T1 (da)
DE (1) DE60219321T2 (da)
DK (1) DK1414858T3 (da)
ES (1) ES2284863T3 (da)
GB (1) GB0110029D0 (da)
MX (2) MXPA03009785A (da)
PT (1) PT1414858E (da)
WO (2) WO2002085944A2 (da)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
GB0228210D0 (en) * 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
WO2004069872A1 (en) * 2003-02-06 2004-08-19 Novozymes A/S Human heavy chain antibody expression in filamentous fungi
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
GB2416768A (en) * 2004-07-22 2006-02-08 Univ Erasmus Heavy chain immunoglobulin complexes
SI2311874T1 (sl) * 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
WO2006036882A2 (en) * 2004-09-24 2006-04-06 Washington University Methods for determining and lowering caffeine concentration in fluids
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
GB0601511D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding Molecules 2
TWI404727B (zh) * 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
JP5105468B2 (ja) * 2006-12-05 2012-12-26 独立行政法人産業技術総合研究所 細胞内で機能する抗体の創製および細胞表現型を制御するタンパク質の同定
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
GB0706628D0 (en) * 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
DK2602323T3 (da) 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Sammensætninger og fremgangsmåder til hæmning af endogene immunglobingener og frembringelse af transgene, humane, idiotypiske antistoffer
EP2220120A2 (en) 2007-11-27 2010-08-25 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
ES2447844T3 (es) 2008-04-03 2014-03-13 Vib Vzw Anticuerpos de dominio individual capaces de modular la actividad BACE1
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
CN104004094B (zh) * 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
EP3470425A3 (en) 2008-12-19 2019-07-17 Ablynx N.V. Immunoglobulins against cell-associatd antigens such as p2x7
WO2010082134A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
PT2491056T (pt) 2009-10-22 2021-10-26 Univ Of Twente Vhh para aplicação na reparação de tecidos, regeneração de órgãos, substituição de órgãos e engenharia de tecidos
US8754287B2 (en) * 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
WO2012025619A1 (en) 2010-08-26 2012-03-01 Vib Vzw Chitinous polysaccharide antigen binding proteins
EA202092589A3 (ru) 2010-11-08 2021-06-30 Аблинкс Н.В. Cxcr2-связывающие полипептиды
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CN104053667B (zh) 2011-06-21 2017-09-15 非营利性组织佛兰芒综合大学生物技术研究所 针对gpcr:g蛋白复合物的结合结构域及来自其的用途
RS59728B1 (sr) 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
EP2753644A1 (en) * 2011-09-09 2014-07-16 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
CN102372779A (zh) * 2011-10-25 2012-03-14 李江伟 具有蒜氨酸酶活性的骆驼单域抗体及制备方法和应用
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
CN102660551B (zh) * 2012-02-09 2014-04-16 陈志南 来源于抗CypA骆驼科动物的重链VHH抗体基因、编码多肽及其应用
MX2014011047A (es) * 2012-03-16 2015-04-08 Regeneron Pharma Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
ES2715279T3 (es) 2012-05-24 2019-06-03 Vib Vzw Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
HRP20231356T1 (hr) * 2012-12-14 2024-02-16 Omniab, Inc. Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže
WO2014118297A1 (en) 2013-01-30 2014-08-07 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
PL2953973T3 (pl) 2013-02-05 2020-01-31 Vib Vzw Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
JP6499090B2 (ja) 2013-03-15 2019-04-10 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 心血管疾患において使用するための抗マクロファージマンノース受容体単一可変ドメイン
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US20160145325A1 (en) * 2013-04-29 2016-05-26 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CN103454413B (zh) * 2013-09-04 2015-03-11 吉日木图 双峰驼特异性抗体制备及免疫检测方法
JP6687525B2 (ja) 2014-01-30 2020-04-22 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ オピオイド受容体結合剤およびその使用
KR102276752B1 (ko) * 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
HUE051088T2 (hu) * 2014-04-08 2021-03-01 Regeneron Pharma Humanizált FC-gamma receptorokkal rendelkezõ nem humán élõlények
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
US10266589B2 (en) 2015-07-29 2019-04-23 Allergan, Inc. Heavy chain only antibodies to ANG-2
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017030909A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
CN109438573B (zh) * 2015-12-25 2020-11-10 中国农业科学院兰州兽医研究所 猪流行性腹泻病毒m蛋白特异性重链抗体
US11001631B2 (en) 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CN105777894A (zh) * 2016-03-12 2016-07-20 长春力太生物技术有限公司 通过转基因啮齿类动物制备人源化驼类单域抗体的方法
CA3017813C (en) 2016-03-17 2021-12-07 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN116987189A (zh) 2016-05-20 2023-11-03 哈普恩治疗公司 单链可变片段cd3结合蛋白质
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
IL264941B2 (en) 2016-08-24 2025-12-01 Teneobio Inc Transgenic non-human animals producing modified heavy chain-only antibodies
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
CN110198955A (zh) 2016-11-23 2019-09-03 哈普恩治疗公司 前列腺特异性膜抗原结合蛋白质
WO2018103093A1 (zh) * 2016-12-09 2018-06-14 深圳华大基因研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
EP3332637A1 (en) * 2016-12-09 2018-06-13 Universitätsklinikum Hamburg-Eppendorf Vhh-containing heavy chain antibody and production thereof
NZ755816A (en) 2017-01-19 2026-03-27 Omniab Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
US12189202B2 (en) 2017-03-24 2025-01-07 Ningbo Sunny Opotech Co., Ltd. Split lens assembly and camera module
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018222587A1 (en) 2017-05-30 2018-12-06 The Regents Of The University Of California NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
HRP20241268T1 (hr) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. Trispecifični proteini i postupci primjene
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US10017560B1 (en) 2017-11-16 2018-07-10 King Saud University Nanobody against begomoviruses
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
JP2021513361A (ja) 2018-02-05 2021-05-27 オリオニス バイオサイエンシーズ，インコーポレイテッド 線維芽細胞結合物質およびその使用
AU2019241350B2 (en) 2018-03-30 2025-10-02 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
US12097219B2 (en) 2018-09-10 2024-09-24 Legend Biotech Ireland Limited Single-domain antibodies against CLL1 and constructs thereof
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
CN114126646B (zh) * 2019-02-27 2025-05-30 浙江纳米抗体技术中心有限公司 基于序列的高通量方法产生骆驼抗体以高分辨率覆盖广泛表位
CA3133648A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
MA56110A (fr) 2019-06-07 2022-04-13 Amgen Inc Constructions de liaison bispécifiques à lieurs clivables de manière sélective
CN112574308A (zh) 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
CA3184351A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
US20230242658A1 (en) * 2020-06-30 2023-08-03 Nona Biosciences (Suzhou) Co., Ltd. 4-1bb-binding protein and use thereof
US20230270086A1 (en) * 2020-07-13 2023-08-31 Kisoji Biotechnology Inc. Transgenic animals expressing heavy chain antibodies
TWI885184B (zh) 2020-07-16 2025-06-01 大陸商和鉑醫藥（上海）有限責任公司 Ｐｄ-１抗原結合蛋白及其應用
EP4255931A1 (en) 2020-12-03 2023-10-11 Amgen Inc. Immunoglobuline constructs with multiple binding domains
WO2022157373A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis
WO2022156908A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method for preparing a lyophilized composition
WO2022156907A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
CA3209052A1 (en) 2021-02-19 2022-08-25 Rafael Cristian CASELLAS Single domain antibodies that neutralize sars-cov-2
WO2022221120A1 (en) 2021-04-16 2022-10-20 Bio-Techne Corporation Camelid anti-severe acute respiratory syndrome coronavirus antibodies
EP4349867A4 (en) 2021-05-28 2026-01-07 Harbour Biomed Shanghai Co Ltd SPECIFIC BINDING PROTEIN TARGETING PD-L1 AND CD73
CN118159559A (zh) 2021-08-18 2024-06-07 和铂医药(上海)有限责任公司 一种抗b7-h4抗体及其制备方法和应用
WO2023057508A1 (en) 2021-10-05 2023-04-13 Vrije Universiteit Brussel Fluorescently labeled immunoglobulin single variable domai ns
EP4490179A1 (en) 2022-03-07 2025-01-15 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
EP4349374A1 (en) 2022-10-05 2024-04-10 Vrije Universiteit Brussel Anti-urokinase plasminogen activator receptor immunoglobulin single variable domains
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
WO2025088085A1 (en) 2023-10-26 2025-05-01 Abscint Nv Image guided biopsy of her2 positive lesions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU3295299A (en) * 1998-02-19 1999-09-06 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60144305D1 (de) 2000-11-17 2011-05-05 Kyowa Hakko Kirin Co Ltd Expression von xenogenen (humanen) Immunglobulinen in klonierten, transgenen Huftieren
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
JP3939160B2 (ja) * 2001-05-25 2007-07-04 独立行政法人科学技術振興機構 腎臓における外来遺伝子発現方法
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
NZ536341A (en) 2002-05-17 2008-05-30 Kirin Holdings Kk Transgenic ungulates capable of human antibody production
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
TWI404727B (zh) * 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除

Also Published As

Publication number Publication date
CA2445253C (en) 2012-04-10
JP2010013479A (ja) 2010-01-21
BR0209207A (pt) 2005-02-09
CY1107669T1 (el) 2013-04-18
WO2002085945A2 (en) 2002-10-31
US20040137570A1 (en) 2004-07-15
DE60219321D1 (de) 2007-05-16
JP2005503129A (ja) 2005-02-03
CA2445255A1 (en) 2002-10-31
WO2002085944A2 (en) 2002-10-31
GB0110029D0 (en) 2001-06-13
JP4418159B2 (ja) 2010-02-17
US20110004949A1 (en) 2011-01-06
MXPA03009785A (es) 2005-03-07
BR0209204A (pt) 2004-07-06
US8507748B2 (en) 2013-08-13
EP1414858A2 (en) 2004-05-06
CN1520424A (zh) 2004-08-11
JP2005503128A (ja) 2005-02-03
EP1414858B1 (en) 2007-04-04
MXPA03009776A (es) 2005-03-07
WO2002085945A3 (en) 2003-03-06
US20040142432A1 (en) 2004-07-22
US20110004948A1 (en) 2011-01-06
US20140033335A1 (en) 2014-01-30
DE60219321T2 (de) 2008-03-20
US8502014B2 (en) 2013-08-06
AU2002256866B2 (en) 2007-06-21
ES2284863T3 (es) 2007-11-16
CN1518559A (zh) 2004-08-04
CA2445253A1 (en) 2002-10-31
CN1520424B (zh) 2012-09-05
PT1414858E (pt) 2007-05-31
ATE358730T1 (de) 2007-04-15
US20140037616A1 (en) 2014-02-06
WO2002085944A3 (en) 2004-03-04
EP1381630A2 (en) 2004-01-21

Similar Documents

Publication Publication Date Title
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
DE60238308D1 (de) Schnellproduktion monoklonaler antikörper
PT1308507E (pt) Anticorpo monoclonal anti-núcleo de hcv
NZ595450A (en) Antibodies to M-CSF
TW200516083A (en) Methods for making dual specificity antibodies
ATE554390T1 (de) Verfahren zur gewinnung von antikörpern
ATE439380T1 (de) Methoden zur herstellung humaner monoklonaler antikörper
HRP20030089B1 (hr) Anti-tnf protutijela, pripravci, postupci i primjena
ATE550352T1 (de) Verfahren zur herstellung von hybridantikörper
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
DE69941453D1 (de) Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
ATE346865T1 (de) Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
DK1506235T3 (da) Fremgangsmåde til produktion af monoklonale antistoffer
ATE370163T1 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
ATE505535T1 (de) Verfahren zur herstellung stabiler b-lymphozyten
WO2005049652A3 (en) Methods of generating antibody diversity in vitro
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies
DE69840561D1 (de) Monoklonaler antikörper, spezifisch für anti-humanes fibrinmonomer, verfahren zur herstellung dessel
BR0204612A (pt) Anticorpos monoclonais antinúcleo de hcv
DE69941961D1 (de) Monoklonale Antikörper gegen humane Thymidylat-Synthase und Hybridomen zu derer Herstellung